|1.||Fuchs, Serge Y: 7 articles (04/2009 - 03/2004)|
|2.||Wang, Yi-Ching: 3 articles (02/2010 - 09/2009)|
|3.||Hsu, Han-Shui: 3 articles (02/2010 - 09/2009)|
|4.||Wei, Shuo: 3 articles (07/2009 - 09/2007)|
|5.||Chen, Ching-Shih: 3 articles (07/2009 - 09/2007)|
|6.||Li, Ying: 3 articles (03/2008 - 03/2005)|
|7.||Benarous, Richard: 3 articles (02/2007 - 01/2006)|
|8.||Pietsch, Torsten: 3 articles (06/2005 - 08/2002)|
|9.||Tzao, Ching: 2 articles (01/2010 - 09/2009)|
|10.||Chuang, Hsiao-Ching: 2 articles (07/2009 - 09/2008)|
01/01/2010 - "HCC tumor tissues with homozygous for 9N ins/ins has the highest level of betaTrCP, which are 3.99 and 7.04-fold higher than heterozygous 9N ins/del and homozygous 9N del/del, respectively. "
01/01/2009 - "These results suggest that F-PBF(beta-TrCP) could be used for cancer treatment by targeted degradation of PTTG1."
03/20/2008 - "Furthermore, we find that beta-TRCP overexpression, which is common in human epithelial cancers, causes oncogenic transformation of human mammary epithelial cells and that this pathogenic function requires REST degradation. "
06/01/2007 - "Our results indicate that the turnover of Mcl-1 by beta-TrCP is an essential mechanism for GSK-3beta-induced apoptosis and contributes to GSK-3beta-mediated tumor suppression and chemosensitization."
06/01/2006 - "Binding of betaTrCP to Gli3 N- and C-terminal domains lacking DSGX2-4S-related motifs was also observed, which could reflect indirect interaction via other components of Hedgehog signaling, such as the tumor suppressor Sufu. "
|2.||Adenomatous Polyposis Coli (Familial Adenomatous Polyposis)
10/30/1999 - "In the absence of an activating signal, phosphorylation of beta-catenin by glycogen synthase kinase 3 (GSK3) acting in conjunction with adenomatous polyposis coli and axin/conductin causes beta-catenin to interact with the beta-transducin repeat-containing protein which results in its ubiquitination and degradation. "
12/05/2008 - "Here we show that the SCF(beta-TrCP) binding site created by phosphorylation of beta-catenin is highly vulnerable to protein phosphatase 2A (PP2A) and must be protected by the adenomatous polyposis coli (APC) tumor suppressor protein. "
05/18/2007 - "This assay revealed that WTX, a protein encoded by a gene mutated in Wilms tumors, forms a complex with beta-catenin, AXIN1, beta-TrCP2 (beta-transducin repeat-containing protein 2), and APC (adenomatous polyposis coli). "
08/10/2002 - "We investigated 37 malignant melanomas (15 primary tumors and 22 metastases) for alterations of 4 genes encoding members of this pathway, i.e., CTNNB1 (beta-catenin gene, 3p22.1), APC (adenomatous polyposis coli gene, 5q22.2), BTRC (beta-transducin repeat-containing protein gene, 10q24.3) and ICAT (inhibitor of beta-catenin and Tcf-4, 1p36.2). "
02/23/2004 - "In several tumour types, TCF/beta-catenin activation is caused by mutations in either adenomatous polyposis coli (APC), beta-catenin exon 3, AXIN1, AXIN2 or beta-transducin repeat-containing protein (beta-TrCP). "
|3.||Lung Neoplasms (Lung Cancer)
01/01/2005 - "Here, we provide evidence to support that beta-TRCP negatively regulates cell growth and motility of lung cancer cells. "
01/01/2005 - "Regulation of lung cancer cell growth and invasiveness by beta-TRCP."
01/15/2010 - "Importantly, SLIT2, betaTrCP, and beta-catenin expression levels predicted postoperative recurrence of lung cancer in patients. "
07/24/2008 - "In addition, a high level of p53 downregulates the beta-catenin expression, but this effect is attenuated by non-functional AXIN2 or betaTrCP in lung cancer."
07/24/2008 - "Ectopic expression and knockdown of p53, AXIN2 and betaTrCP genes in A549 (p53 wild-type) and H1299 (p53 null) lung cancer cell lines showed cooperation between p53 and AXIN2/betaTrCP in the reduction of beta-catenin expression. "
|4.||Squamous Cell Carcinoma (Epidermoid Carcinoma)
|5.||Breast Neoplasms (Breast Cancer)
03/23/2006 - "We report here for the first time that interaction between PRLr and beta-TrCP is less efficient in human breast cancer cells than in non-tumorigenic human mammary epithelial cells. "
03/01/2005 - "Here we show that inhibition of beta-TrCP either by RNAi approach or by forced expression of a dominant-negative beta-TrCP mutant suppresses growth and survival of human breast cancer cells. "
04/01/2009 - "PRLr is commonly stabilized in human breast cancer due to decreased phosphorylation of residue Ser349, which when phosphorylated recruits the betaTrcp E3 ubiquitin ligase and facilitates PRLr degradation. "
03/01/2008 - "The PRLr is commonly stabilized in human breast cancer due to decreased phosphorylation of residue Ser(349), which, when phosphorylated, recruits the beta Trcp E3 ubiquitin ligase and facilitates PRLr degradation. "
03/01/2005 - "Targeting beta-transducin repeat-containing protein E3 ubiquitin ligase augments the effects of antitumor drugs on breast cancer cells."
|1.||beta-Transducin Repeat-Containing Proteins
|3.||Proteins (Proteins, Gene)
|4.||Glycogen Synthase Kinases
|5.||glycogen synthase kinase 3 beta
|7.||Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)
|9.||Proteasome Endopeptidase Complex (Proteasome)